Show simple item record

dc.contributor.authorAnderson, Diana*
dc.contributor.authorNajafzadeh, Mojgan*
dc.contributor.authorGopalan, Rajendran C.*
dc.contributor.authorGhaderi, Nader*
dc.contributor.authorScally, Andy J.*
dc.contributor.authorBritland, Stephen T.*
dc.contributor.authorJacobs, B.J.*
dc.contributor.authorReynolds, P.D.*
dc.contributor.authorDavies, J.*
dc.contributor.authorWright, A.L.*
dc.contributor.authorAl-Ghazal, S.*
dc.contributor.authorSharpe, D.*
dc.contributor.authorDenyer, Morgan C.T.*
dc.date.accessioned2015-09-30T14:02:49Z
dc.date.available2015-09-30T14:02:49Z
dc.date.issued2014-10-28
dc.identifier.citationAnderson D, Najafzadeh M, Gopalan R et al (2014) Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics. The FASEB Journal. 28(10): 4563-4570.en_US
dc.identifier.urihttp://hdl.handle.net/10454/7410
dc.descriptionNoen_US
dc.description.abstractLymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, and 4 with lung cancer (58), 18 with suspected melanoma, 28 with polyposis, and 10 with COPD (56), and 94 healthy volunteers were examined. The natural logarithm of the Olive tail moment (OTM) was plotted for exposure to UVA through 5 different agar depths (100 cell measurements/depth) and analyzed using a repeated measures regression model. Responses of patients with cancer plateaued after treatment with different UVA intensities, but returned toward control values for healthy volunteers. For precancerous conditions and suspected cancers, intermediate responses occurred. ROC analysis of mean log OTMs, for cancers plus precancerous/suspect conditions vs. controls, cancer vs. precancerous/suspect conditions plus controls, and cancer vs. controls, gave areas under the curve of 0.87, 0.89, and 0.93, respectively (P<0.001). Optimization allowed test sensitivity or specificity to approach 100% with acceptable complementary measures. This modified comet assay could represent a stand-alone test or an adjunct to other investigative procedures for detecting cancer.en_US
dc.language.isoenen_US
dc.subjectBlood testen_US
dc.subjectSusceptibility
dc.subjectCancer diagnostics
dc.subjectLymphocyte genome sensitivity (LGS) assay
dc.titleSensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnosticsen_US
dc.status.refereedYesen_US
dc.date.Accepted2014-06-30
dc.typeArticleen_US
dc.type.versionNo full-text available in the repositoryen_US
dc.identifier.doihttps://doi.org/10.1096/fj.14-254748


This item appears in the following Collection(s)

Show simple item record